News & Updates
Filter by Specialty:
Nivolumab-chemo poised to alter NSCLC treatment landscape
In the 3-year analysis of the phase III CheckMate 816 trial, neoadjuvant nivolumab plus platinum doublet chemotherapy (nivo-chemo) continued to provide durable benefit for individuals with resectable non-small-cell lung cancer (NSCLC).
Nivolumab-chemo poised to alter NSCLC treatment landscape
06 Jun 2023
Atopic dermatitis poses heightened risk of venous thromboembolism
Adults with atopic dermatitis appear to have an increased risk of venous thromboembolism (VTE), although the risk difference relative to adults without AD is quite small, as reported in a study.
Atopic dermatitis poses heightened risk of venous thromboembolism
03 Jun 2023
First-line TB treatment: Faropenem rivals ethambutol in efficacy, with fewer side effects
Faropenem, when used in combination with the other standard treatment drugs for the first-line treatment of tuberculosis (TB) infection, appears to be noninferior to ethambutol, with faropenem having the added benefit of lower frequency of adverse events (AEs), according to the results of an open-label study in China.
First-line TB treatment: Faropenem rivals ethambutol in efficacy, with fewer side effects
31 May 2023
Paediatric TB care riddled with uncertainty, study says
Uncertainty weighs heavily on managing tuberculosis (TB) infection in children, with multi-level factors influencing the decision-making regarding testing and treatment.
